37 citations
,
September 2003 in “Journal of Medicinal Chemistry” A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.
44 citations
,
October 2016 in “Epilepsia” 2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.
5 citations
,
September 2015 in “Medical hypotheses” Topical sulfonylurea may reduce excessive hair growth caused by certain medications.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
January 2024 in “Wiadomości Lekarskie” Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
July 2024 in “Reactions Weekly” 
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
January 2022 in “Drugs of Today” 1 citations
,
January 2025 in “ARC Journal of Dermatology” 
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
May 2024 in “Reactions weekly” July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
May 2024 in “Reactions weekly” 
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
3 citations
,
September 2008 in “Current signal transduction therapy” Drugs that block GSK-3 show promise for treating various diseases.
61 citations
,
January 2015 in “Hormones” Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
121 citations
,
April 2008 in “The Journal of Clinical Endocrinology & Metabolism” Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.
1 citations
,
May 1992 in “Pharmacological Research”